Skip to Content

JavaScript has been disabled within your browser, the content or the functionality of this web page can be limited or unavailable.

There is no panel matching the key "Alert---Site-Wide"

Quick Access Links

Clinical Trials Search Results

Search for

in

Accepting Participants (14)
In Progress (1)

Showing 1-10 of 14

Sorted By:

A-Z
Z-A

Previous Next

(NSABP B-64) EXActDNA-003: Breast Cancer Clinical Validation Study to Predict Recurrence of High-Risk Early Breast Cancer Treated with Neoadjuvant Therapy Using a Bespoke Circulating Tumor DNA Assay to Detect Molecular Residual Disease
participants planning to undergo chemo for high-risk, early breast cancer, who are willing to provide tissue and blood specimens for circulating tumor DNA (ctDNA) analysis
A011801: The COMPASSHER2 Trials (Comprehensive Use of Pathologic Response Assessment to Optimize Therapy in HER2-Positive Breast Cancer): COMPASSHER2 Residual Disease (RD), A Double-blinded, Phase III Randomized Trial of T-DM1 and Placebo Compared with T-DM1 and Tucatinib (Location: Yankton)
This phase III trial studies how well trastuzumab emtansine (T-DM1) and tucatinib work in preventing breast cancer from coming back (relapsing) in patients with high risk, HER2 positive breast cancer. T-DM1 is a monoclonal antibody, called trastuzumab, linked to a chemotherapy drug, called DM1.
A021806: A Phase III Trial of Perioperative Versus Adjuvant Chemotherapy for Resectable Pancreatic Cancer
A PHASE III TRIAL OF PERIOPERATIVE VERSUS ADJUVANT CHEMOTHERAPY FOR RESECTABLE PANCREATIC CANCER
A022104: The JANUS Rectal Cancer Trial: A Randomized Phase II Trial Testing the Efficacy of Triplet Versus Doublet Chemotherapy to Achieve Clinical Complete Response in Patients with Locally Advanced Rectal Cancer
A022104: JANUS Rectal Cancer Trial: A Randomized Phase II Trial Testing the Efficacy of Triplet Versus Doublet Chemotherapy
A031902: CASPAR - A Phase III Trial of Enzalutamide and Rucaparib as a Novel Therapy in First-Line Metastatic Castration-Resistant Prostate Cancer (Location: Yankton)
This randomized, placebo-controlled phase III trial is evaluating the benefit of rucaparib and enzalutamide combination therapy versus enzalutamide alone for the treatment of men with prostate cancer that has spread to other places in the body (metastatic) and has become resistant to testosterone-deprivation therapy (castration-resistant).
AstraZeneca_AZD5305 evoPAR: A Randomized, 2-cohort, Double-blind, Placebo-controlled, Phase III Study of Saruparib (AZD5305) in Combination with Physician’s Choice New Hormonal Agents in Patients with HRRm and non-HRRm Metastatic Castration-Sensitive Prostate Cancer (EvoPAR-Prostate01)
2-cohort, Double-blind, Placebo-controlled, Study with Physician’s Choice New Hormonal Agents in Patients with Prostate Cancer
CAMBRIA-1: A Phase III, Open-Label, Randomised Study to Assess the Efficacy & Safety of Extended Therapy with Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) versus Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) in Patients with ER+/HER2- Early Breast Cancer & an Intermediate or High Risk of Recurrence Who Have Completed Definitive Locoregional Therapy and at Least 2 Years of Standard Adjuvant Endocrine-Based Therapy Without Disease Recurrence
camizestrant vs ET in patients w/ ER+/HER2- early BC w/ risk for disease recurrence who completed treatment & adjuvant ET for 2-5 years. Duration of treatment is 60 months
GSK_219606 AZUR-2: A Phase 3, Open-Label, Randomized Study of Perioperative Dostarlimab Monotherapy Versus Standard of Care in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer
Phase 3, Open-Label, Randomized Study of Perioperative Dostarlimab Monotherapy vs Standard of Care in Pts With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer
Merck_MK5684-003: A Phase 3 Randomized, Open-label Study of MK-5684 Versus Alternative Abiraterone Acetate or Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) Previously Treated With Next-generation Hormonal Agent (NHA) and Taxane-based Chemotherapy
Ph 3 Randomized, Open-label Study of MK-5684 vs Alternative Abiraterone Acetate or Enzalutamide in pts w/ mCRPC Prev. Treated w/ NHA) & Taxane-based Chemotherapy
Merck_MK5684-004: A Phase 3, Randomized, Open-label Study of MK-5684 Versus Alternative Abiraterone Acetate or Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) That Progressed On or After Prior Treatment With One Next-generation Hormonal Agent (NHA)
Ph 3 Study of MK-5684 vs Alt.Abiraterone Acetate or Enzalutamide in Pts w/ mCRPC) that Progressed On /After Prior Treatment With One Next-generation Hormonal Agent (NHA)

Previous Next